Lupin Launches HIV Drug in US, Eligible for 180-Day Generic Exclusivity

Lupin said it launched Raltegravir Tablets USP, 600 mg, in the United States after FDA approval of its abbreviated new drug application. The company is the exclusive first-to-file, according to the report.